

Errata

Volume 30 (2010), No 6, page 2209:
Affiliations 1 and 2 should read:

¹*The Comprehensive Cancer Center of Drum Tower Hospital Affiliated to the Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, P.R. China;*
²*Department of General Surgery, Drum Tower Hospital Affiliated to the Medical School of Nanjing University, Nanjing, P.R. China;*

Volume 30 (2010), No 7, page 2884:
Acknowledgements should be inserted before References:

Acknowledgements

This research was supported in part by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Grant No. 2010-0010840) (to EHA).

Volume 30 (2010), No 7, page 2978, right column:
Line 26 should read:
patients with samples drawn at Bu dose numbers 1, 5, 9 and 13 (18).

Volume 30 (2010), No 7, page 2980, Table II, fifth column, line 6:
38.2 should be replaced by 68.2.

Volume 30 (2010), No 7, page 2980, Table II, seventh column, line 13:
82.3 should be replaced by 52.3.

Volume 30 (2010), No 7, page 2988:
Tables I and II should be inserted before the Discussion:

Table I. Demographic characteristics of patients according to study.

Characteristics	Day 8 study (n=55)	Day 1 study (n=55)	Total (n=110)
Gender			
Male (%)	41 (74.5)	32 (58.2)	73 (66.4)
Female (%)	14 (25.5)	23 (41.8)	37 (33.6)
Histological type			
Squamous (%)	14 (25.5)	7 (12.7)	21 (19.1)
Non-squamous (%)	41 (74.5)	48 (87.3)	89 (80.9)
Stage			
IIIB (%)	10 (18.2)	14 (25.5)	24 (21.8)
IV (%)	45 (81.8)	41 (74.5)	86 (78.2)
Age (years)			
<70 (%)	42 (76.4)	47 (85.5)	89 (80.9)
≥70 (%)	13 (23.6)	8 (14.5)	21 (19.1)
Performance status (ECOG)			
0 (%)	30 (54.5)	20 (36.4)	50 (45.5)
1 (%)	23 (41.8)	35 (63.6)	58 (52.7)
2 (%)	2 (3.6)	NA	2 (1.8)

NA: not applicable; ECOG: Eastern Cooperative Oncology Group scale.

Table II. Overall response rates according to histological type in the two studies analysed*.

	Overall (%)	Squamous cell carcinoma (%)	Non-squamous cell carcinoma (%)
Day 8 study	18/55 (32.7)	8/14 (57.1)	18/41 (43.9)
Day 1 study	26/55 (47.3)	2/7 (28.6)	16/48 (33.3)
Total	44/110 (40.0)	10/21 (47.6)	34/89 (38.2)

*No. of patients who responded/No. of patients treated.